A VC's decision to nominate a portfolio company for corporate investor consideration spends more than relationship capital. It directs management attention, reveals something about the fund's priorities and introduces a potential shareholder whose interests may differ from those of existing investors. The nomination therefore deserves the same discipline as other consequential portfolio decisions, even though it commits no new capital.
The strongest starting question is whether a particular corporate relationship could improve the company's options. Fundraising urgency matters, but it cannot establish corporate relevance. Treating these as separate judgments produces a clearer case for the founder, the nominating VC and the prospective CVC.
Test corporate relevance independently of cash need
M12 describes support for its portfolio companies through access to Microsoft's tools, services and expertise. This is a specific corporate programme's proposition, not evidence that every CVC offers equivalent resources.[1]
For a nomination, translate any proposed corporate advantage into a testable thesis. Which capability could matter to the company? Why is this corporate investor plausibly positioned to help? What evidence would show the relationship is adding value, and what would the company need to contribute?
Capital need belongs in a separate assessment. A company can have a compelling corporate fit without needing an immediate financing. Another can face urgent fundraising pressure while having little reason to favour corporate capital. Combining the two assessments prematurely invites generic claims about strategic value to cover a weak investment case.
Management time has an opportunity cost. Nomination quality includes deciding which conversations should not begin yet.
Explain what the existing investor wants
A nomination carries an implicit endorsement, but its meaning is ambiguous. The VC may want a partner with technical expertise, additional capital for expansion, a different shareholder mix or relief from a constrained reserve budget. Several motives can coexist.
The nominating partner should write down the company's objective and the fund's objective separately. Where do they align? Where could they diverge? A financing that preserves the fund's ownership or protects an earlier valuation may still be unattractive to the company if it introduces restrictive strategic terms or consumes too much management time.
The existing investor's experience can provide valuable context. A credible nomination makes that perspective legible: how long the VC has invested, what has changed since its original thesis and why this particular corporate discussion is useful now.
Put reserves and participation in context
British Business Bank's Enterprise Capital Funds criteria request information on capital retained for follow-on investments and on arrangements for managing follow-ons. Reserve policy is therefore an explicit part of that programme's assessment of fund strategy.[2]
For a portfolio nomination, the practical implication is to explain the existing investor's expected participation without turning it into a simplistic quality signal. A fund may be constrained by concentration limits, investment period, reserve availability or mandate. It may also have changed its view of the company. An outsider cannot reliably distinguish those explanations from silence.
State what is decided, what remains under review and what conditions apply. If the VC expects to invest, distinguish a working intention from an approved commitment. If it does not expect to invest, explain the relevant constraint or investment judgment accurately, without disclosing unrelated confidential fund information.
The context should help the CVC ask informed questions and reach its own conclusion.
Make founder consent specific
British Business Bank's venture capital checklist encourages companies to research prospective investors, including their previous investments and the value they can add. That guidance puts evaluation of the investor on the company's side of the relationship too.[3]
Founder consent to a nomination should reflect that agency. Confirm who may receive the company's name, which materials may be shared and what purpose the conversation serves. Consent to an initial introduction should not be treated as blanket agreement to disclose a detailed customer list or negotiate financing terms.
Discuss strategic sensitivities before outreach. Could affiliation with the corporate group complicate relationships with other customers? Could the requested information expose a product roadmap? The company should assess those questions in context.
Use staged disclosure where appropriate and let the company decide when a deeper exchange is justified. Agree how changes will be handled if the founder's priorities shift.
Reduce information asymmetry without becoming an advocate at any price
An existing investor knows the company's history and may understand why a difficult quarter differs from a weakening business. It also has incentives that a new investor must interpret. A nomination limited to the fundraising story can obscure valuable context and unresolved problems.
Separate observed facts, management forecasts and the VC's interpretation. Describe the evidence behind the corporate thesis, identify material uncertainties and explain which information the company has authorised for sharing. If a milestone moved, discuss what changed rather than quietly replacing the previous target.
Consider this hypothetical example. A VC backs an industrial software company with eight months of runway. The fund has limited reserves. A CVC's parent could offer useful sector expertise, but the startup sells to several competing manufacturers. The founder authorises an initial discussion using anonymised customer information.
The nomination explains both the strategic hypothesis and the VC's limited expected participation. The CVC still evaluates the investment independently. A serious discussion can then test whether the prospective benefits justify the information exposure and potential customer concerns. An introduction alone resolves none of those questions.
Use a nomination memo to make the decision reviewable
A short internal memo can prevent the portfolio list from becoming a queue ordered solely by fundraising pressure. It should capture the reason to act, the reason to hesitate and the evidence needed to change the assessment. Use these questions to make the reasoning explicit.
| Decision area | Question before nomination |
|---|---|
| Company objective | What outcome does the founder want from this corporate relationship? |
| Corporate relevance | What specific capability or strategic interest supports the fit? |
| Financing timing | Is the discussion for a next round, an add-on investment or future consideration? |
| VC incentives | What does the fund gain, and where could that differ from the company's interest? |
| Reserves and signalling | What participation is expected, approved or constrained, and why? |
| Founder consent | Which recipients, materials and purposes has the company approved? |
| Information gaps | What remains uncertain, and who can provide authorised evidence? |
Treat membership as access to a process
Through CVCVC, an international association, VC firms pay an annual firm membership to nominate consenting portfolio companies. Approved CVCs can publish mandates and RFPs free of charge. A nomination may seek CVC participation in the company's next round or an add-on investment.
Membership does not determine investment merit. CVCs retain independent investment decisions and diligence. If a discussion develops into separately scoped syndication work, fees are agreed upfront.
A good portfolio process should also learn from nominations that go nowhere. Reconsider the fit, timing and information provided without treating every decline as a verdict on the company. Use that assessment to improve future nominations.
Sources & further reading
Sources support the factual references. The frameworks and illustrative examples are CVCVC analysis.
Syndication 
Portfolio conversations